Free tool
Drug Trial Radar: Ophthalmology
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
555
Completed, industry sponsors, Ophthalmology, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed555
555 trials
Showing 1 to 25, recently updated first.
- RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)Pivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT04567550 · 139 participants · Start Nov 20, 2020 · Primary completion Jun 18, 2026
Drug: Topical Steroid; Aflibercept · For: Diabetic Retinopathy (DR); Center-Involved Diabetic Macular Edema (CI-DME)
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 25 sites in all
- A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic AtrophyPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT06722157 · 202 participants · Start Jan 6, 2025 · Primary completion Oct 26, 2026
Drug: BI 771716; Pegcetacoplan and 1 more · For: Macular Degeneration, Age-related; Geographic Atrophy
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 46 sites in all
- Next Generation RocklatanPivotal-lookingCompleted
Alcon ResearchIndustry
NCT06441643 · 646 participants · Start Sep 4, 2024 · Primary completion Nov 14, 2025
Drug: AR-17043 Ophthalmic Solution; PG043 Ophthalmic Solution and 4 more · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Dothan, Alabama; Phoenix, Arizona; Garden Grove, California · 25 sites in all
- A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)Pivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04968912 · 163 participants · Start Sep 21, 2021 · Primary completion Oct 23, 2023
Drug: Nipocalimab; Standard of Care Treatment · For: Sjogren's Syndrome
Sites: Anniston, Alabama; Glendale, Arizona; Mesa, Arizona · 69 sites in all
EyeBiotech Ltd.Industry
NCT05919693 · 33 participants · Start Jun 12, 2023 · Primary completion Aug 26, 2024
Drug: Remigromig · For: Neovascular Age-related Macular Degeneration (NVAMD); Diabetic Macular Edema (DME)
Sites: Phoenix, Arizona; Bakersfield, California; Modesto, California · 32 sites in all
Qlaris Bio, Inc.Industry
NCT07354477 · 9 participants · Start Feb 20, 2026 · Primary completion Oct 1, 2026
Drug: QLS-111 Ophthalmic Solution (0.015%); QLS-111 Ophthalmic Solution (0.075%) · For: Non-proliferative Diabetic Retinopathy (NPDR); Open-angle Glaucoma (OAG); Normal Tension Glaucoma (NTG)
Sites: Palo Alto, California
- Study of the Safety and Efficacy of APX3330 in Diabetic RetinopathyPivotal-lookingCompleted
Opus Genetics, IncIndustry
NCT04692688 · 103 participants · Start Apr 8, 2021 · Primary completion Jan 25, 2023
Drug: APX3330; Placebo · For: Diabetic Retinopathy; Diabetic Macular Edema; NPDR - Non Proliferative Diabetic Retinopathy and 1 more
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 24 sites in all
Opus Genetics, IncIndustry
NCT03960866 · 39 participants · Start May 28, 2019 · Primary completion Sep 11, 2019
Drug: Phentolamine Mesylate Ophthalmic Solution 1% · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Mission Hills, California; Morrow, Georgia; Ann Arbor, Michigan · 5 sites in all
- A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular DegenerationPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT05230537 · 168 participants · Start Feb 17, 2022 · Primary completion Aug 19, 2026
Drug: Iptacopan (LNP023); Placebo · For: Age-Related Macular Degeneration
Sites: Fullerton, California; Huntington Beach, California; Rancho Cordova, California · 28 sites in all
- A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic AtrophyPivotal-lookingCompleted
Annexon, Inc.Industry
NCT04656561 · 270 participants · Start Feb 26, 2021 · Primary completion Mar 28, 2023
Drug: ANX007 · For: Geographic Atrophy
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 53 sites in all
- Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular DegenerationPivotal-lookingCompleted
Kyowa Kirin Co., Ltd.Industry
NCT06116890 · 170 participants · Start Jan 31, 2024 · Primary completion Jun 3, 2026
Drug: KHK4951; Aflibercept Injection · For: Neovascular Age-Related Macular Degeneration (nAMD)
Sites: Mesa, Arizona; Tucson, Arizona; Arcadia, California · 84 sites in all
BioNanoSim Ltd.Industry
NCT07869953 · 18 participants · Start Mar 7, 2024 · Primary completion Mar 25, 2025
Drug: Oftac: 0.05% tacrolimus ophthalmic emulsion · For: Non-Infectious Anterior Uveitis
Sites: Beersheba, Israel; Haifa, Israel; Jerusalem, Israel · 7 sites in all
- Evaluation of BTV100 in Subjects With Dry Eye DiseasePivotal-lookingCompleted
BioTheraVision, Inc.Industry
NCT06543303 · 123 participants · Start Dec 31, 2024 · Primary completion Jan 14, 2026
Drug: BTV100 Low dose; BTV100 Mid dose and 2 more · For: Dry Eye
Sites: Doncaster East, Australia; Sydney, Australia; Kaohsiung City, Taiwan · 6 sites in all
EnnovaBioIndustry
NCT06708260 · 60 participants · Start Dec 12, 2024 · Primary completion Aug 12, 2026
Drug: ENN0403, low dose; ENN0403, high dose · For: Diabetic Macular Edema (DME)
Sites: Shijiazhuang, China; Xingtai, China; Zhengzhou, China · 9 sites in all
Invirsa, Inc.Industry
NCT06599684 · 19 participants · Start Sep 7, 2024 · Primary completion Sep 30, 2025
Drug: INV-102 · For: Non-center Involved Diabetic Macular Edema; Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy; Diabetic Retinopathy and 2 more
Sites: Dallas, Texas
- QA102 Phase II Study in Subjects With Dry AMDPivotal-lookingCompleted
Smilebiotek Zhuhai LimitedIndustry
NCT05536752 · 150 participants · Start Sep 22, 2022 · Primary completion Nov 12, 2024
Drug: QA102/Placebo; QA102 and 1 more · For: Dry Age-related Macular Degeneration
Sites: Phoenix, Arizona; Mountain View, California; Pasadena, California · 29 sites in all
- Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye DiseasePivotal-lookingCompleted
Invirsa, Inc.Industry
NCT06370039 · 109 participants · Start Mar 27, 2024 · Primary completion Jul 3, 2024
Drug: INV-102; Vehicle · For: Dry Eye Disease
Sites: Rush, New York
Invirsa, Inc.Industry
NCT05586152 · 84 participants · Start Aug 30, 2022 · Primary completion May 2, 2023
Drug: INV-102; Vehicle · For: Dry Eye Disease
Sites: Rush, New York
- A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)Pivotal-lookingCompleted
Aviceda Therapeutics, Inc.Industry
NCT05839041 · 300 participants · Start May 2, 2023 · Primary completion Feb 18, 2026
Drug: AVD-104; Avacincaptad · For: Geographic Atrophy of the Macula; Macular Degeneration
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 56 sites in all
- Study of Zifibancimig in Participants With Neovascular Age-related Macular DegenerationPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04567303 · 177 participants · Start Oct 28, 2020 · Primary completion Aug 25, 2026
Drug: Zifibancimig; Ranibizumab · For: Macular Degeneration
Sites: Mesa, Arizona; Phoenix, Arizona; Encino, California · 37 sites in all
Ocular Therapeutix, Inc.Industry
NCT05335122 · 83 participants · Start Mar 16, 2022 · Primary completion Jan 24, 2024
Drug: OTX-TIC low dose Travoprost Intracameral Implant; OTX-TIC high dose Travoprost Intracameral Implant and 1 more · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Dothan, Alabama; Huntington Beach, California; Irvine, California · 30 sites in all
SoligenixIndustry
NCT06386744 · 8 participants · Start Nov 18, 2024 · Primary completion May 23, 2025
Drug: Dusquetide · For: Behçet Disease
Sites: Istanbul, Turkey (Türkiye)
EyeBiotech Ltd.Industry
NCT06664502 · 38 participants · Start Nov 12, 2024 · Primary completion Mar 25, 2026
Drug: EYE201 · For: Diabetic Macular Edema (DME); Neovascular Age-related Macular Degeneration (NVAMD); BRVO - Branch Retinal Vein Occlusion
Sites: Scottsdale, Arizona; Modesto, California; Mountain View, California · 27 sites in all
- Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Qlaris Bio, Inc.Industry
NCT07354516 · 64 participants · Start Mar 18, 2026 · Primary completion Jul 22, 2026
Drug: Latanoprost (0.005%) · For: OAG - Open-Angle Glaucoma; OHT - Ocular Hypertension
Sites: Largo, Florida
- Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT07168902 · 252 participants · Start Oct 24, 2025 · Primary completion May 18, 2026
Drug: BL1107 Low dose; BL1107 High dose and 1 more · For: Glaucoma
Sites: Glendale, California; Newport Beach, California; Pasadena, California · 14 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.